



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 09/864,078
Applicants: : LaColla *et al.*
Filed : May 23, 2001
TC/A.U. : 1623
Examiner : Howard V. Owens, Jr.

Confirmation No. 9998

Docket No. : 06171.105022 (IDX 1007 US)
Customer No. : 20786

Mail Stop ISSUE FEE
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

April 29, 2004

Terminal Disclaimer

Sir:

Assignees, Idenix Pharmaceuticals Inc. and the Universita Degli Studi Di Cagliari, the owners of the entire interest of U.S. Serial Nos. 09/864,078 and 09/863,816, through the undersigned agent of record, hereby disclaim the terminal part of any patent granted on U.S. Serial No. 09/864,078 that would extend beyond the expiration date of the full statutory term of U.S. Serial No. 09/863,816. Any patent granted on U.S. Serial No. 09/864,078 shall be enforceable only for and during such period that legal title to the patent that issues from U.S. Serial No. 09/864,078 shall be the same as legal title to the patent that issues from U.S. Serial No. 09/863,816 and will be binding upon the grantee, its successors or assigns.

Jean Pierre Sommadossi has assigned U.S. Serial Nos. 09/864,078 and 09/863,816 to Novirio Pharmaceuticals Limited, while Paola LaColla has assigned U.S. Serial Nos. 09/864,078 and 09/863,816 to the Universita Degli Studi Di Cagliari, whose addresses are of record, in Assignments recorded on February 26, 2001, at Reel 011545, Frame 0275 (for U.S. Serial Nos. 09/864,078 and 09/863,816).

FEE ONLY

02/01/2005 DHARTINO 00000001 110980 09864078

01 FC:1814 110.00 DA